Notice of Corporate Officer Changes
June 28th, 2023, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that it will dissolve the Executive Management Team (EMT) and establish a new executive structure on July 1, 2023, in line with the start of the new medium-term management plan. In addition, selected executives among the Corporate Officers will be appointed as a Corporate Management Member (CMM) to review and discuss key issues that are of particular importance from a company-wide management perspective, with the aim of enabling quick and effective decision-making.
List of Corporate Officers effective July 1, 2023
| Name | New Position | Current Position |
|---|---|---|
| Takeshi Ito* | Representative Director of the Board, President, Chief Executive Officer | Representative Director of the Board, President, Chief Executive Officer |
| Rie Nakajima* | Corporate Officer Chief Operating Officer Head of North America Business | Corporate Officer Chief Operating Officer |
| Ippei Kurihara* | Corporate Officer Head of Japan Business, Head of Japan Sales and Marketing Division, Head of Marketing Department | Corporate Officer Head of Japan Business, Head of Japan Sales and Marketing Division, Head of Marketing Department |
| Marianthi Psaha | Corporate Officer Head of Europe, Middle East and Africa (EMEA) Business | Corporate Officer Global Head, Cell & Gene Business Segment |
| Shinichi Teramachi | Corporate Officer Head of Sales Department, Japan Sales and Marketing Division | Corporate Officer Head of Sales Department, Japan Sales and Marketing Division |
| Takayuki Yamada | Corporate Officer Head of China Business | Corporate Officer Head of China Business |
| Chris Reindel | Corporate Officer Chief Commercialization & Portfolio Officer | Corporate Officer Chief Commercialization & Portfolio Officer |
| Robert Wagner | Corporate Officer Global Head, Medical Tech Solutions Business Segment | Corporate Officer Global Head, Medical Tech Solutions Business Segment |
| Yoshinori Watanabe | Corporate Officer Head of Sales and Marketing Division – OTC products | Head of Sales and Marketing Division – OTC products |
| Reza Haque* | Corporate Officer Head of Ophthalmology Innovation Center | Corporate Officer Head of Ophthalmology Innovation Center |
| Peter Sallstig* | Corporate Officer Chief Medical Officer | Corporate Officer Chief Medical Officer |
| Fumiyasu Ako* | Corporate Officer Chief of Staff to CEO | Corporate Officer Chief of Staff to CEO |
| Ken Araki* | Corporate Officer Global Head of Business Development | Corporate Officer Global Head of Business Development |
| Frank Binder | Corporate Officer Head of Supply Chain Division | Corporate Officer Head of Supply Chain Division |
| Mark Dawson* | Corporate Officer Chief Product Supply Officer | Corporate Officer Chief Product Supply Officer |
| Minori Hara* | Corporate Officer Chief Digital & Information Officer | Corporate Officer Chief Digital & Information Officer |
| Nobuko Kato | Corporate Officer Chief Communications Officer | Corporate Officer Chief Communications Officer |
| Kazuo Koshiji* | Corporate Officer Chief Financial Officer & Chief Risk Officer | Corporate Officer Chief Financial Officer & Chief Risk Officer |
| Mika Masunari* | Corporate Officer General Counsel & Chief Compliance Officer | Corporate Officer General Counsel & Chief Compliance Officer |
| Takahiro Morita | Corporate Officer Global Head of Core Principle & Sustainability | Corporate Officer Global Head of Core Principle & Sustainability |
| Yoko Saiki* | Corporate Officer Global Head of Corporate Strategy | Corporate Officer Global Head of Corporate Strategy |
* Corporate Management Member (CMM)
About Santen
As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (https://www.santen.com/en).
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
Official SNS
